Dietary Fat Type 1,3-DAG Boosts GLP-1 and PYY Through Gut Bacteria in Diabetic Rats

Male Wistar rats were fed a high-fat, high-sugar diet with weekly STZ injections (30 mg/kg) for 4 weeks to induce T2DM. After confirming stable hyperglycemia, rats were randomized to: healthy control, T2DM model, low-dose 1,3-DAG (50% DAG + 50% TAG), and high-dose 1,3-DAG (100% DAG) for 8 weeks. Outcomes included fasting glucose, insulin, lipids, colonic histology, GPR41 expression, GLP-1, PYY, serum LPS, 16S microbiota sequencing, and fecal SCFA levels by GC.

GLP-1 and PYY are peptide hormones central to blood sugar and appetite regulation. While drugs like semaglutide provide these hormones externally, this study shows a dietary intervention that naturally boosts the body's own production of these peptides through the gut microbiome. This could offer an accessible, food-based complementary approach to diabetes management.

The gut microbiome's role in metabolic health is a rapidly expanding field. This study connects dietary fat composition to endogenous peptide hormone production through a clear mechanistic pathway: 1,3-DAG → beneficial gut bacteria → short-chain fatty acids → GPR41 receptor activation → GLP-1/PYY release. As interest grows in food-as-medicine approaches to diabetes, understanding how specific dietary components affect peptide hormone signaling could transform nutritional recommendations.

This is an animal study using a chemical (STZ) diabetes model that may not fully replicate human type 2 diabetes. Specific group sizes were not stated in the abstract. The 8-week duration is relatively short. The causal pathway (microbiota → SCFA → GPR41 → GLP-1) is correlative in this study — direct causation would require microbiota transfer or GPR41 knockout experiments. Human studies are needed to confirm whether dietary 1,3-DAG produces similar effects.